Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739554 · ClinicalTrials.gov registry record · Phase 1
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
A Phase 1 study of Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 3
- Study locations
NCT03739554: Completed Phase 1 study of Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by Cyclacel Pharmaceuticals.
NCT03739554 is a Phase 1 study of Relapsed or Refractory Chronic Lymphocytic Leukemia that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03739554, a Phase 1 study of Relapsed or Refractory Chronic Lymphocytic Leukemia, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG CYC065
Study Locations (3)
Maryland
- Investigational Site - Baltimore
North Carolina
- Investigational Site - Charlotte
Texas
- Investigational Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2023-04-27 |
| Phase | Phase 1 |
What the finished NCT03739554 record still lists
NCT03739554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Relapsed or Refractory Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT03739554 reports a single indexed study location in Maryland, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT03739554 about?
NCT03739554 is a clinical study titled "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL". A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
What is the current status of trial NCT03739554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-01-25. Estimated completion is 2023-04-27.
What conditions does trial NCT03739554 study?
This clinical trial studies the following conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT03739554?
The interventions under investigation include: Venetoclax (DRUG), CYC065 (DRUG).
Who is sponsoring clinical trial NCT03739554?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03739554 being conducted?
This trial has 3 study locations across Maryland, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03739554's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI